Enesia Banda Chaponda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Enesia Banda Chaponda has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Chandramohan
London School of Hygiene and Tropical Medicine, London, UK
3 shared publications - R. Matthew Chico
London School of Hygiene and Tropical Medicine
3 shared publications Charles Michelo
Department of Epidemiology, School of Public Health, University of Zambia, Lusaka, Zambia
2 shared publications- Charles Michelo
Nkwazi Research University
2 shared publications - James Chipeta
Department of Paediatrics and Child Health, University of Zambia School of Medicine, Lusaka, Zambia
2 shared publications Jane Bruce
Department of Disease Control, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
2 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by Elsevier in SSRN Electronic Journal
Impact of Metronidazole With Monthly Intermittent Preventive Treatment of Malaria Using Sulfadoxine-Pyrimethamine or Dihydroartemisinin-Piperaquine on Adverse Pregnancy Outcomes and Curable Sexually Transmitted Infections: A Double-Blind Randomised, Partly Placebo-controlled Trial in Zambia
Background: Despite widespread Plasmodium falciparum resistance, intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine–pyrimethamine is more protective against adverse pregnancy and birth outcomes compared to IPTp with dihydroartemisinin–piperaquine, even though dihydroartemisinin–piperaquine is superior against malaria-related outcomes. We assessed whether adding metronidazole to sulfadoxine–pyrimethamine is more protective against adverse pregnancy and birth outcomes compared to IPTp with dihydroartemisinin–piperaquine in an area of high malaria transmission and parasite resistance to sulfadoxine–pyrimethamine, and where curable sexually transmitted infections (STIs) in pregnancy, including bacterial vaginosis, are common. Methods: From December 2019 to March 2022, we enrolled pregnant women without HIV into ASPIRE, an individually randomised, double-blinded, three-arm, partly placebo-controlled trial in Zambia. Participants received monthly IPTp with standard sulfadoxine–pyrimethamine (3 tablets 500mg sulfadoxine and 25mg pyrimethamine) plus placebo metronidazole in Arm 1, or standard sulfadoxine–pyrimethamine plus metronidazole (4 tablets 500mg) in Arm 2, or dihydroartemisinin-piperaquine plus metronidazole (3 tablets 40mg dihydroartemisinin and 320mg piperaquine once daily for 3 consecutive days) plus metronidazole (4 tablets 500mg) in Arm 3. The primary outcome was any adverse pregnancy or birth outcome (spontaneous abortion, stillbirth, low birthweight, preterm birth, or neonatal death). Secondary outcomes included components of the primary outcome, small-for-gestational age, and day 28 treatment efficacy of IPTp regimens against asymptomatic Plasmodium falciparum malaria infection and asymptomatic curable STIs. We used a modified intention-to-treat analysis for the primary outcome. ClinicalTrials.gov: NCT04189744. Findings: 5436 pregnant women were allocated to three treatment-arms. Overall, 16·3% (288/1763) of women in Arm 1 (reference) had adverse pregnancy and birth outcomes compared to 16·6% (290/1745) in Arm 2 (p=0·82), and 16·0% (281/1755) in Arm 3 (p=0·79). Of individual components of adverse pregnancy and birth outcomes in the primary outcome, none differed across arms. However, women in Arm 3 were at greater risk of delivering small-for-gestational age newborns relative to Arm 1, 28·4% (476/1678) vs 24·5% (408/1663) (p=0·01). In Arms 1, 2, and 3, the day 28 clearance of asymptomatic peripheral malaria detected by PCR was 72·1% (555/770), 71·8% (541/754), and 93·5% (722/772), respectively. In Arm 1, day 28 clearance of asymptomatic STIs by PCR, and bacterial vaginosis by microscopy using the Nugent score, were: Chlamydia trachomatis 98·4% (60/61), Neisseria gonorrhoea 84·1% (95/113), Trichomonas vaginalis 75·0% (96/128), and bacterial vaginosis 34·3% (193/563). In Arm 2, day 28 clearance rates were: C. trachomatis 89·5% (51/57), N. gonorrhoea 84·2% (96/114), T. vaginalis 87·5% (105/120), and bacterial vaginosis 53·9% (289/536). In Arm 3, day 28 clearance rates were: C. trachomatis 80·8% (42/52), N. gonorrhoea 84·9% (84/99), T. vaginalis 89·8% (115/128), and bacterial vaginosis 62·2% (335/536). Interpretation: Neither Arm 2 nor 3 were superior to Arm 1 for protection against adverse pregnancy and birth outcomes. Arm 3 was superior to Arms 1 and 2 against malaria infection, whereas all IPTp regimens reduced curable STIs, including bacterial vaginosis. Sulfadoxine-pyrimethamine may serve as an important tool fo
- 1 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImpact of Metronidazole With Monthly Intermittent Preventive Treatment of Malaria Using Sulfadoxine-Pyrimethamine or Dihydroartemisinin-Piperaquine on Adverse Pregnancy Outcomes and Curable Sexually Transmitted Infections: A Double-Blind Randomised, Partly Placebo-controlled Trial in Zambia
Background: Despite widespread Plasmodium falciparum resistance, intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine–pyrimethamine is more protective against adverse pregnancy and birth outcomes compared to IPTp with dihydroartemisinin–piperaquine, even though dihydroartemisinin–piperaquine is superior against malaria-related outcomes. We assessed whether adding metronidazole to sulfadoxine–pyrimethamine is more protective against adverse pregnancy and birth outcomes compared to IPTp with dihydroartemisinin–piperaquine in an area of high malaria transmission and parasite resistance to sulfadoxine–pyrimethamine, and where curable sexually transmitted infections (STIs) in pregnancy, including bacterial vaginosis, are common. Methods: From December 2019 to March 2022, we enrolled pregnant women without HIV into ASPIRE, an individually randomised, double-blinded, three-arm, partly placebo-controlled trial in Zambia. Participants received monthly IPTp with standard sulfadoxine–pyrimethamine (3 tablets 500mg sulfadoxine and 25mg pyrimethamine) plus placebo metronidazole in Arm 1, or standard sulfadoxine–pyrimethamine plus metronidazole (4 tablets 500mg) in Arm 2, or dihydroartemisinin-piperaquine plus metronidazole (3 tablets 40mg dihydroartemisinin and 320mg piperaquine once daily for 3 consecutive days) plus metronidazole (4 tablets 500mg) in Arm 3. The primary outcome was any adverse pregnancy or birth outcome (spontaneous abortion, stillbirth, low birthweight, preterm birth, or neonatal death). Secondary outcomes included components of the primary outcome, small-for-gestational age, and day 28 treatment efficacy of IPTp regimens against asymptomatic Plasmodium falciparum malaria infection and asymptomatic curable STIs. We used a modified intention-to-treat analysis for the primary outcome. ClinicalTrials.gov: NCT04189744. Findings: 5436 pregnant women were allocated to three treatment-arms. Overall, 16·3% (288/1763) of women in Arm 1 (reference) had adverse pregnancy and birth outcomes compared to 16·6% (290/1745) in Arm 2 (p=0·82), and 16·0% (281/1755) in Arm 3 (p=0·79). Of individual components of adverse pregnancy and birth outcomes in the primary outcome, none differed across arms. However, women in Arm 3 were at greater risk of delivering small-for-gestational age newborns relative to Arm 1, 28·4% (476/1678) vs 24·5% (408/1663) (p=0·01). In Arms 1, 2, and 3, the day 28 clearance of asymptomatic peripheral malaria detected by PCR was 72·1% (555/770), 71·8% (541/754), and 93·5% (722/772), respectively. In Arm 1, day 28 clearance of asymptomatic STIs by PCR, and bacterial vaginosis by microscopy using the Nugent score, were: Chlamydia trachomatis 98·4% (60/61), Neisseria gonorrhoea 84·1% (95/113), Trichomonas vaginalis 75·0% (96/128), and bacterial vaginosis 34·3% (193/563). In Arm 2, day 28 clearance rates were: C. trachomatis 89·5% (51/57), N. gonorrhoea 84·2% (96/114), T. vaginalis 87·5% (105/120), and bacterial vaginosis 53·9% (289/536). In Arm 3, day 28 clearance rates were: C. trachomatis 80·8% (42/52), N. gonorrhoea 84·9% (84/99), T. vaginalis 89·8% (115/128), and bacterial vaginosis 62·2% (335/536). Interpretation: Neither Arm 2 nor 3 were superior to Arm 1 for protection against adverse pregnancy and birth outcomes. Arm 3 was superior to Arms 1 and 2 against malaria infection, whereas all IPTp regimens reduced curable STIs, including bacterial vaginosis. Sulfadoxine-pyrimethamine may serve as an important tool fo
- Open Access
- 30 January 2021
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 21 (1) , 1-10
Assessment of syndromic management of curable sexually transmitted and reproductive tract infections among pregnant women: an observational cross-sectional study
Background: This study estimated the prevalence of curable sexually transmitted and reproductive tract infections (STIs/RTIs) among pregnant women attending antenatal care (ANC) in rural Zambia, evaluated the effectiveness of syndromic management of STIs/RTIs versus reference-standard laboratory diagnoses, and identified determinants of curable STIs/RTIs during pregnancy. Methods: A total of 1086 pregnant women were enrolled at ANC booking, socio-demographic information and biological samples were collected, and the provision of syndromic management based care was documented. The Piot-Fransen model was used to evaluate the effectiveness of syndromic management versus etiological testing, and univariate and multivariate logistic regression analyses were used to identify determinants of STIs/RTIs. Results: Participants had a mean age of 25.6 years and a mean gestational age of 22.0 weeks. Of 1084 women, 700 had at least one STI/RTI (64.6%; 95% confidence interval [CI], 61.7, 67.4). Only 10.2% of infected women received any treatment for a curable STI/RTI (excluding syphilis). Treatment was given to 0 of 56 women with chlamydia (prevalence 5.2%; 95% CI, 4.0, 6.6), 14.7% of participants with gonorrhoea (prevalence 3.1%; 95% CI, 2.2, 4.4), 7.8% of trichomoniasis positives (prevalence 24.8%; 95% CI, 22.3, 27.5) and 7.5% of women with bacterial vaginosis (prevalence 48.7%; 95% CI, 45.2, 51.2). An estimated 7.1% (95% CI, 5.6, 8.7) of participants had syphilis and received treatment. Women < 20 years old were more likely (adjusted odds ratio [aOR] = 5.01; 95% CI: 1.23, 19.44) to have gonorrhoea compared to women ≥30. The odds of trichomoniasis infection were highest among primigravidae (aOR = 2.40; 95% CI: 1.69, 3.40), decreasing with each subsequent pregnancy. Women 20 to 29 years old were more likely to be diagnosed with bacterial vaginosis compared to women ≥30 (aOR = 1.58; 95% CI: 1.19, 2.10). Women aged 20 to 29 and ≥ 30 years had higher odds of infection with syphilis, aOR = 3.96; 95% CI: 1.40, 11.20 and aOR = 3.29; 95% CI: 1.11, 9.74 respectively, compared to women under 20. Conclusions: Curable STIs/RTIs were common and the majority of cases were undetected and untreated. Alternative approaches are urgently needed in the ANC setting in rural Zambia.
- 30 January 2021
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 21 (1) , 1-10
Open AccessAssessment of syndromic management of curable sexually transmitted and reproductive tract infections among pregnant women: an observational cross-sectional study
Background: This study estimated the prevalence of curable sexually transmitted and reproductive tract infections (STIs/RTIs) among pregnant women attending antenatal care (ANC) in rural Zambia, evaluated the effectiveness of syndromic management of STIs/RTIs versus reference-standard laboratory diagnoses, and identified determinants of curable STIs/RTIs during pregnancy. Methods: A total of 1086 pregnant women were enrolled at ANC booking, socio-demographic information and biological samples were collected, and the provision of syndromic management based care was documented. The Piot-Fransen model was used to evaluate the effectiveness of syndromic management versus etiological testing, and univariate and multivariate logistic regression analyses were used to identify determinants of STIs/RTIs. Results: Participants had a mean age of 25.6 years and a mean gestational age of 22.0 weeks. Of 1084 women, 700 had at least one STI/RTI (64.6%; 95% confidence interval [CI], 61.7, 67.4). Only 10.2% of infected women received any treatment for a curable STI/RTI (excluding syphilis). Treatment was given to 0 of 56 women with chlamydia (prevalence 5.2%; 95% CI, 4.0, 6.6), 14.7% of participants with gonorrhoea (prevalence 3.1%; 95% CI, 2.2, 4.4), 7.8% of trichomoniasis positives (prevalence 24.8%; 95% CI, 22.3, 27.5) and 7.5% of women with bacterial vaginosis (prevalence 48.7%; 95% CI, 45.2, 51.2). An estimated 7.1% (95% CI, 5.6, 8.7) of participants had syphilis and received treatment. Women < 20 years old were more likely (adjusted odds ratio [aOR] = 5.01; 95% CI: 1.23, 19.44) to have gonorrhoea compared to women ≥30. The odds of trichomoniasis infection were highest among primigravidae (aOR = 2.40; 95% CI: 1.69, 3.40), decreasing with each subsequent pregnancy. Women 20 to 29 years old were more likely to be diagnosed with bacterial vaginosis compared to women ≥30 (aOR = 1.58; 95% CI: 1.19, 2.10). Women aged 20 to 29 and ≥ 30 years had higher odds of infection with syphilis, aOR = 3.96; 95% CI: 1.40, 11.20 and aOR = 3.29; 95% CI: 1.11, 9.74 respectively, compared to women under 20. Conclusions: Curable STIs/RTIs were common and the majority of cases were undetected and untreated. Alternative approaches are urgently needed in the ANC setting in rural Zambia.
- Open Access
- 22 January 2021
- Published by Springer Nature in Malaria Journal
- Vol. 20 (1) , 1-10
Sulfadoxine-pyrimethamine parasitological efficacy against Plasmodium falciparum among pregnant women and molecular markers of resistance in Zambia: an observational cohort study
Background: The World Health Organization recommends the provision of intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) at 4-week intervals from gestational week 13 to delivery in areas of moderate to high malaria transmission intensity. However, the effect of IPTp-SP has been compromised in some areas due to parasite resistance, raising the importance of parasitological and chemoprophylactic surveillance, and monitoring SP-resistance markers in the Plasmodium falciparum population. Methods: Between November 2013 and April 2014 in Nchelenge, Zambia, 1086 pregnant women received IPTp-SP at antenatal-care bookings. Blood samples were collected on day 0, and on day 28 post-treatment to test for malaria parasites and to estimate SP parasitological efficacy in the treatment and prevention of parasitaemia. A random sample of 96, day 0 malaria-positive samples were analysed to estimate the prevalence of SP-resistance markers in the P. falciparum population. Results: The overall parasitological and prophylactic failure among women who had paired day 0 and day 28 blood slides was 18.6% (95% CI 15.5, 21.8; 109 of 590). Among pregnant women who had asymptomatic parasitaemia on day 0, the day 28 PCR-uncorrected parasitological failure was 30.0% (95% CI 23.7, 36.2; 62 of 207) and the day 28 PCR-corrected parasitological failure was 15.6% (95% CI: 10.6, 20.6; 32 of 205). Among women who tested negative at day 0, 12.3% (95% CI: 9.0, 15.6; 47 of 383) developed parasitaemia at day 28. Among the 96 malaria-positive samples assayed from day 0, 70.8% (95% CI: 60.8, 79.2) contained the DHPS double (Gly-437 + Glu-540) mutation and 92.7% (95% CI: 85.3, 96.5) had the DHFR triple (Asn-108 + Ile-51 + Arg-59) mutation. The quintuple mutation (DHFR triple + DHPS double) and the sextuple mutant (DHFR triple + DHPS double + Arg-581) were found among 68.8% (95% CI: 58.6, 77.3) and 9.4% (95% CI: 4.2, 16.0) of samples, respectively. Conclusion: The parasitological and chemoprophylactic failure of SP, and the prevalence of resistance markers in Nchelenge is alarmingly high. Alternative therapies are urgently needed to safeguard pregnant women against malarial infection.
- 22 January 2021
- Published by Springer Nature in Malaria Journal
- Vol. 20 (1) , 1-10
Open AccessSulfadoxine-pyrimethamine parasitological efficacy against Plasmodium falciparum among pregnant women and molecular markers of resistance in Zambia: an observational cohort study
Background: The World Health Organization recommends the provision of intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) at 4-week intervals from gestational week 13 to delivery in areas of moderate to high malaria transmission intensity. However, the effect of IPTp-SP has been compromised in some areas due to parasite resistance, raising the importance of parasitological and chemoprophylactic surveillance, and monitoring SP-resistance markers in the Plasmodium falciparum population. Methods: Between November 2013 and April 2014 in Nchelenge, Zambia, 1086 pregnant women received IPTp-SP at antenatal-care bookings. Blood samples were collected on day 0, and on day 28 post-treatment to test for malaria parasites and to estimate SP parasitological efficacy in the treatment and prevention of parasitaemia. A random sample of 96, day 0 malaria-positive samples were analysed to estimate the prevalence of SP-resistance markers in the P. falciparum population. Results: The overall parasitological and prophylactic failure among women who had paired day 0 and day 28 blood slides was 18.6% (95% CI 15.5, 21.8; 109 of 590). Among pregnant women who had asymptomatic parasitaemia on day 0, the day 28 PCR-uncorrected parasitological failure was 30.0% (95% CI 23.7, 36.2; 62 of 207) and the day 28 PCR-corrected parasitological failure was 15.6% (95% CI: 10.6, 20.6; 32 of 205). Among women who tested negative at day 0, 12.3% (95% CI: 9.0, 15.6; 47 of 383) developed parasitaemia at day 28. Among the 96 malaria-positive samples assayed from day 0, 70.8% (95% CI: 60.8, 79.2) contained the DHPS double (Gly-437 + Glu-540) mutation and 92.7% (95% CI: 85.3, 96.5) had the DHFR triple (Asn-108 + Ile-51 + Arg-59) mutation. The quintuple mutation (DHFR triple + DHPS double) and the sextuple mutant (DHFR triple + DHPS double + Arg-581) were found among 68.8% (95% CI: 58.6, 77.3) and 9.4% (95% CI: 4.2, 16.0) of samples, respectively. Conclusion: The parasitological and chemoprophylactic failure of SP, and the prevalence of resistance markers in Nchelenge is alarmingly high. Alternative therapies are urgently needed to safeguard pregnant women against malarial infection.
- Open Access
- 2 November 2016
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 95 (5) , 1069-1076
Malarial Infection and Curable Sexually Transmitted and Reproductive Tract Infections Among Pregnant Women in a Rural District of Zambia
Malarial infection and curable sexually transmitted and reproductive tract infections (STIs/RTIs) are important causes of adverse birth outcomes. Reducing the burden of these infections in pregnancy requires interventions that can be easily integrated into the antenatal care (ANC) package. However, efforts to integrate the control of malarial infection and curable STIs/RTIs in pregnancy have been hampered by a lack of evidence related to their coinfection. Thus, we investigated the prevalence of coinfection among pregnant women of rural Zambia. A prospective cohort study was conducted in Nchelenge District, Zambia, involving 1,086 first ANC attendees. We screened participants for peripheral malarial infection and curable STIs/RTIs (syphilis, Chlamydia, gonorrhea, trichomoniasis, and bacterial vaginosis), and collected relevant sociodemographic data at booking. Factors associated with malarial and STI/RTI coinfection were explored using univariate and multivariate regression models. Among participants with complete results (N = 1,071), 38.7% (95% confidence interval [CI] = 35.7–41.6) were coinfected with malaria parasites and at least one STI/RTI; 18.9% (95% CI = 16.5–21.2) were infected with malaria parasites only; 26.0% (95% CI = 23.5–28.8) were infected with at least one STI/RTI but no malaria parasites, and 16.4% (95% CI = 14.1–18.6) had no infection. Human immunodeficiency virus (HIV)-infected women had a higher risk of being coinfected than HIV-uninfected women (odds ratio [OR] = 3.59 [95% CI = 1.73–7.48], P < 0.001). The prevalence of malarial and STI/RTI coinfection was high in this population. An integrated approach to control malarial infection and STIs/RTIs is needed to reduce this dual burden in pregnancy.
- 2 November 2016
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 95 (5) , 1069-1076
Open AccessMalarial Infection and Curable Sexually Transmitted and Reproductive Tract Infections Among Pregnant Women in a Rural District of Zambia
Malarial infection and curable sexually transmitted and reproductive tract infections (STIs/RTIs) are important causes of adverse birth outcomes. Reducing the burden of these infections in pregnancy requires interventions that can be easily integrated into the antenatal care (ANC) package. However, efforts to integrate the control of malarial infection and curable STIs/RTIs in pregnancy have been hampered by a lack of evidence related to their coinfection. Thus, we investigated the prevalence of coinfection among pregnant women of rural Zambia. A prospective cohort study was conducted in Nchelenge District, Zambia, involving 1,086 first ANC attendees. We screened participants for peripheral malarial infection and curable STIs/RTIs (syphilis, Chlamydia, gonorrhea, trichomoniasis, and bacterial vaginosis), and collected relevant sociodemographic data at booking. Factors associated with malarial and STI/RTI coinfection were explored using univariate and multivariate regression models. Among participants with complete results (N = 1,071), 38.7% (95% confidence interval [CI] = 35.7–41.6) were coinfected with malaria parasites and at least one STI/RTI; 18.9% (95% CI = 16.5–21.2) were infected with malaria parasites only; 26.0% (95% CI = 23.5–28.8) were infected with at least one STI/RTI but no malaria parasites, and 16.4% (95% CI = 14.1–18.6) had no infection. Human immunodeficiency virus (HIV)-infected women had a higher risk of being coinfected than HIV-uninfected women (odds ratio [OR] = 3.59 [95% CI = 1.73–7.48], P < 0.001). The prevalence of malarial and STI/RTI coinfection was high in this population. An integrated approach to control malarial infection and STIs/RTIs is needed to reduce this dual burden in pregnancy.
- Open Access
- 30 September 2015
- Published by Springer Nature in Malaria Journal
- Vol. 14 (1) , 1-12
High burden of malaria infection in pregnant women in a rural district of Zambia: a cross-sectional study
Malaria continues to be a major health problem in low-income countries. Consequently, malaria control remains a public health priority in endemic countries such as Zambia. Pregnant women and children under 5 years of age are among groups at high risk of malaria infection. Malaria infection is associated with adverse birth outcomes that affect the mother, foetus, and infant. Infection with HIV has been shown to increase the risk of malaria infection in pregnancy. The prevalence and the predictors of malaria infection among pregnant women resident in the Nchelenge District of northern Zambia were investigated. Between November 2013 and April 2014, pregnant women in the catchment areas of two health centres were recruited during their first antenatal care visit. HIV testing was conducted as part of routine care. In addition, blood samples were collected from 1086 participants and tested for malaria infection using standard microscopy and polymerase chain reaction (PCR) techniques specific for Plasmodium falciparum. Multivariate logistic regression were conducted to examine the predictors of malaria infection. The prevalence of malaria identified by microscopy was 31.8 % (95 % confidence intervals [CI], 29.0–34.5; N = 1079) and by PCR was 57.8 % (95 % CI, 54.9–60.8; N = 1074). HIV infection was 13.2 % among women on their first antenatal visit; the prevalence of malaria detected by PCR among HIV-uninfected and HIV-infected women was 56.7 % (531/936) and 65.2 % (90/138), respectively. In the final model, the risk of malaria infection was 81 % higher among pregnant women recruited from Nchelenge health centre compared to those attending the Kashikishi health centre (adjusted odds ratio = 1.81; 95 % CI, 1.38–2.37, P < 0.001), and HIV-infected women across health centres had a 46 % greater risk of malaria infection compared to HIV-uninfected women (adjusted odds ratio = 1.46; 95 %, 1.00–2.13, P = 0.045). High burden of malaria detected by PCR in these pregnant women suggests that past prevention efforts have had limited effect. To reduce this burden of malaria sustainably, there is clear need to strengthen existing interventions and, possibly, to change approaches so as to improve targeting of groups most affected by malaria.
- 30 September 2015
- Published by Springer Nature in Malaria Journal
- Vol. 14 (1) , 1-12
Open AccessHigh burden of malaria infection in pregnant women in a rural district of Zambia: a cross-sectional study
Malaria continues to be a major health problem in low-income countries. Consequently, malaria control remains a public health priority in endemic countries such as Zambia. Pregnant women and children under 5 years of age are among groups at high risk of malaria infection. Malaria infection is associated with adverse birth outcomes that affect the mother, foetus, and infant. Infection with HIV has been shown to increase the risk of malaria infection in pregnancy. The prevalence and the predictors of malaria infection among pregnant women resident in the Nchelenge District of northern Zambia were investigated. Between November 2013 and April 2014, pregnant women in the catchment areas of two health centres were recruited during their first antenatal care visit. HIV testing was conducted as part of routine care. In addition, blood samples were collected from 1086 participants and tested for malaria infection using standard microscopy and polymerase chain reaction (PCR) techniques specific for Plasmodium falciparum. Multivariate logistic regression were conducted to examine the predictors of malaria infection. The prevalence of malaria identified by microscopy was 31.8 % (95 % confidence intervals [CI], 29.0–34.5; N = 1079) and by PCR was 57.8 % (95 % CI, 54.9–60.8; N = 1074). HIV infection was 13.2 % among women on their first antenatal visit; the prevalence of malaria detected by PCR among HIV-uninfected and HIV-infected women was 56.7 % (531/936) and 65.2 % (90/138), respectively. In the final model, the risk of malaria infection was 81 % higher among pregnant women recruited from Nchelenge health centre compared to those attending the Kashikishi health centre (adjusted odds ratio = 1.81; 95 % CI, 1.38–2.37, P < 0.001), and HIV-infected women across health centres had a 46 % greater risk of malaria infection compared to HIV-uninfected women (adjusted odds ratio = 1.46; 95 %, 1.00–2.13, P = 0.045). High burden of malaria detected by PCR in these pregnant women suggests that past prevention efforts have had limited effect. To reduce this burden of malaria sustainably, there is clear need to strengthen existing interventions and, possibly, to change approaches so as to improve targeting of groups most affected by malaria.